-
호텔 10명 중 4명은 예약 후 씨트립, 투우 등 6대 플랫폼을 취소할 수 없다
남도기자가 알아본데 따르면 최근 소비자의 합법적권익을 수호하고 량호한 소비환경을 조성하기 위해 광동성소비자위원회는"온라인관광플랫폼 호텔예약취소규칙조사"를 조직, 전개했다. 플랫폼이 제공한 서비스협의 ... -
Over 40% of hotel bookings cannot be cancelled after being booked, and six major platforms including Ctrip and Tuniu have been interviewed
Southern Metropolis Daily reporter learned that recently, in order to safeguard the legitimate rights and interests of consumers and create a good consumption environment, the Guangdong Provincial Co ... -
Google develops ping pong robot with over 40% win rate against humans
DeepMind, a subsidiary of Google, announced that its team has developed a table tennis robot that can reach the level of human amateur table tennis players in competitions. The research and developme ... -
A bouquet of roses costs 9.9 yuan, and fresh flowers such as horse embroidered balls are discounted by nearly 40% in summer
"Nowadays, flowers are really getting cheaper and almost on par with vegetables." In the construction of a Damao store in Yuexiu District, Guangzhou, customer Xiao Yang found that roses only cost 9.9 ... -
US media reports that Boeing has not passed nearly 40% of regulatory audits
@CCTV International News: According to the New York Times on March 11th local time, the Federal Aviation Administration of the United States found that Boeing had "many quality control issues" after ... -
Baidu's net profit will increase by nearly 40% in 2023 Robin Lee: the big model will bring about 660 million incremental revenue for cloud business
Baidu has released its financial reports for the fourth quarter and full year of 2023. According to the financial report, Baidu's total revenue in 2023 was 134.598 billion yuan, a year-on-year increa ... -
Baidu's net profit will increase by nearly 40% in 2023 Robin Lee: the big model will bring about 660 million incremental revenue for cloud business
Science and Technology Innovation Board Daily, February 29th (Reporter Huang Xinyi) Baidu has released its financial reports for the fourth quarter and full year of 2023. According to the financial r ... -
Cornell Bio's core products released the latest data, followed by a sharp drop of nearly 40% in stock price
On November 21st, Cornell Bio announced IL-4R α 52 week clinical data on the treatment of moderate to severe atopic dermatitis with monoclonal antibody drug Rademikabart. According to the official w ...